Imodium

Loperamide Hydrochloride, the active ingredient in Imodium, is a peripheral opioid agonist presented as an oral tablet for oral use. It is used to reduce the frequency and urgency of stools in acute and chronic diarrheal conditions, including irritable bowel syndrome with diarrhea. By slowing intestinal motility and enhancing water absorption, it helps normalize stool consistency and frequency, providing symptomatic relief for patients of various ages.

GNH USA supplies Imodium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imodium (loperamide) acts on the gastrointestinal tract to reduce excessive bowel movements associated with diarrheal disorders.

Acute nonspecific diarrhea: reduces stool frequency and improves consistency within hours. Chronic diarrhea: provides ongoing control of stool output for patients with persistent diarrheal symptoms. Irritable bowel syndrome with diarrhea: alleviates urgency and frequency, supporting symptom management.

Loperamide is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Constipation - Abdominal cramps - Nausea - Dizziness - Dry mouth - Headache

Serious or Rare Side Effects: - Severe constipation leading to bowel obstruction - Toxic megacolon - Allergic reactions such as rash, itching, or swelling - Cardiac arrhythmias, including QT prolongation - Paralytic ileus - Severe abdominal pain

Before initiating therapy, consider the following precautions.

Assess severity: confirm that diarrhea is not caused by infection before use. Avoid in patients with known hypersensitivity to loperamide. Do not use in children under 2 years without medical advice. Limit use in patients with hepatic impairment due to reduced metabolism. Avoid concurrent use with strong CYP3A4 inhibitors without supervision. Store at room temperature: keep in original container, protect from moisture and heat.

Loperamide may interact with several medicines; review the following categories.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase plasma loperamide levels, risk of cardiotoxicity. - CYP2C8 inhibitors (e.g., gemfibrozil): elevate concentrations, potential toxicity. - Other antidiarrheals (e.g., diphenoxylate): additive opioid effects. - QT‑prolonging drugs (e.g., quinidine): heightened risk of arrhythmia.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may increase constipation. - Antifungal azoles (e.g., itraconazole): moderate increase in loperamide exposure. - Ritonavir: may raise levels, monitor cardiac status.